Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
Tevogen Bio (NASDAQ:TVGN) announced plans to disclose detailed valuations of its significant internally developed assets, which are currently not reflected on the company's balance sheet under U.S. GAAP rules. The company's key assets include three granted and twelve pending U.S. patents, including two in artificial intelligence.
Tevogen highlighted its proprietary ExacTcell™ platform for developing CD8+ cytotoxic T lymphocytes, and AI technologies including PredicTcell™ and AdapTcell™, developed through strategic partnerships with Microsoft and Databricks. The company's clinical pipeline focuses on cancer therapeutics with potential expansion into non-oncology indications.
The company maintains drug discovery facilities at CIC Philadelphia, headquarters in New Jersey, and is developing internal GMP manufacturing capabilities. Tevogen reports being well-capitalized with access to a line of credit for current operations.
Tevogen Bio (NASDAQ:TVGN) ha annunciato l'intenzione di rendere pubbliche valutazioni dettagliate dei suoi principali asset sviluppati internamente, attualmente non contabilizzati nel bilancio secondo i principi U.S. GAAP. Tra questi rientrano tre brevetti statunitensi concessi e dodici in fase di domanda, di cui due relativi all'intelligenza artificiale.
La società ha evidenziato la sua piattaforma proprietaria ExacTcell™ per lo sviluppo di linfociti T citotossici CD8+, oltre alle tecnologie AI PredicTcell™ e AdapTcell™, sviluppate in partnership strategiche con Microsoft e Databricks. Il programma clinico è incentrato su terapie oncologiche, con possibili estensioni a indicazioni non oncologiche.
Tevogen dispone di strutture per la scoperta di farmaci presso CIC Philadelphia, ha la sede centrale nel New Jersey e sta sviluppando capacità interne di produzione GMP. L'azienda riferisce di essere ben capitalizzata e di avere accesso a una linea di credito per le attività correnti.
Tevogen Bio (NASDAQ:TVGN) anunció que divulgará valoraciones detalladas de sus principales activos desarrollados internamente, los cuales actualmente no aparecen en el balance conforme a las normas U.S. GAAP. Entre estos activos figuran tres patentes otorgadas en EE. UU. y doce en trámite, incluidas dos relacionadas con inteligencia artificial.
La compañía destacó su plataforma propia ExacTcell™ para desarrollar linfocitos T citotóxicos CD8+, así como las tecnologías de IA PredicTcell™ y AdapTcell™, desarrolladas en asociaciones estratégicas con Microsoft y Databricks. Su cartera clínica se centra en terapias contra el cáncer, con potencial expansión a indicaciones no oncológicas.
Tevogen mantiene instalaciones de descubrimiento de fármacos en CIC Philadelphia, tiene su sede en Nueva Jersey y está desarrollando capacidades internas de fabricación GMP. La empresa informa estar bien capitalizada y contar con una línea de crédito para sus operaciones actuales.
Tevogen Bio (NASDAQ:TVGN)는 현재 미국 GAAP 규정에 따라 재무제표에 반영되지 않은 주요 내부 개발 자산의 상세한 평가액을 공개할 계획이라고 발표했습니다. 주요 자산에는 미국에서 허가된 특허 3건 및 출원 중인 특허 12건(그중 2건은 인공지능 관련)이 포함됩니다.
회사는 CD8+ 세포독성 T 림프구를 개발하는 독자 플랫폼 ExacTcell™과 Microsoft 및 Databricks와의 전략적 제휴를 통해 개발된 AI 기술인 PredicTcell™ 및 AdapTcell™를 강조했습니다. 임상 파이프라인은 암 치료제에 중점을 두고 있으며 비종양성 적응증으로의 확장 가능성을 보유하고 있습니다.
Tevogen은 CIC Philadelphia에 약물 발굴 시설을 보유하고 본사는 뉴저지에 있으며, 내부 GMP 제조 역량을 개발 중입니다. 또한 회사는 자본 상태가 양호하며 현재 운영을 위한 신용한도 이용이 가능하다고 보고했습니다.
Tevogen Bio (NASDAQ:TVGN) a annoncé son intention de publier des évaluations détaillées de ses principaux actifs développés en interne, qui ne figurent actuellement pas au bilan selon les règles U.S. GAAP. Parmi ces actifs se trouvent trois brevets américains délivrés et douze en instance, dont deux portant sur l'intelligence artificielle.
L'entreprise a mis en avant sa plateforme propriétaire ExacTcell™ pour le développement de lymphocytes T cytotoxiques CD8+, ainsi que ses technologies d'IA PredicTcell™ et AdapTcell™, développées en partenariat stratégique avec Microsoft et Databricks. Son portefeuille clinique cible des thérapies oncologiques, avec un potentiel d'extension à des indications non oncologiques.
Tevogen dispose d'installations de découverte de médicaments au CIC Philadelphia, d'un siège dans le New Jersey, et met en place des capacités internes de production GMP. La société déclare être bien capitalisée et avoir accès à une ligne de crédit pour ses opérations courantes.
Tevogen Bio (NASDAQ:TVGN) hat angekündigt, detaillierte Bewertungen seiner bedeutenden intern entwickelten Vermögenswerte offenzulegen, die derzeit nach U.S. GAAP nicht in der Bilanz ausgewiesen sind. Zu den Schlüsselwerten gehören drei erteilte und zwölf anhängige US-Patente, davon zwei im Bereich künstliche Intelligenz.
Das Unternehmen hob seine proprietäre ExacTcell™-Plattform zur Entwicklung von CD8+-zytotoxischen T-Lymphozyten hervor sowie die KI-Technologien PredicTcell™ und AdapTcell™, die in strategischen Partnerschaften mit Microsoft und Databricks entwickelt wurden. Die klinische Pipeline konzentriert sich auf Krebstherapien mit möglicher Ausweitung auf Indikationen außerhalb der Onkologie.
Tevogen unterhält Wirkstoffforschungsanlagen im CIC Philadelphia, hat seinen Hauptsitz in New Jersey und baut interne GMP-Fertigungskapazitäten auf. Das Unternehmen gibt an, gut kapitalisiert zu sein und über eine Kreditlinie für den laufenden Betrieb zu verfügen.
- Three granted U.S. patents and twelve pending patents, including two in AI technology
- Strategic partnerships with major tech companies Microsoft and Databricks
- Multiple proprietary platforms: ExacTcell™, PredicTcell™, and AdapTcell™
- Well-capitalized with access to line of credit
- Expanding facilities including drug discovery lab and planned GMP manufacturing capabilities
- Internally developed assets not reflected on balance sheet under GAAP rules
- Limited operating history as mentioned in risk factors
- Need to raise additional capital to execute business plan
- Significant regulatory and development risks in therapeutic pipeline
WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company’s balance sheet, yet represent substantial long-term value. Tevogen will provide detailed information and valuation of these assets in the coming days.
Tevogen’s key assets include:
- Intellectual Property Portfolio – Three wholly owned, granted U.S. patents and twelve pending U.S. patents, including two in artificial intelligence.
- Drug Development Platforms – ExacTcell™: highly purified, target-specific CD8+ cytotoxic T lymphocytes (CTL).
- Artificial Intelligence Technology & Partnerships – Strategic collaborations with Microsoft and Databricks supporting:
• PredicTcell™, AI algorithms predicting peptide–T cell receptor interactions, accelerating development and expanding Tevogen’s pipeline.
• AdapTcell™, AI models decoding HLA–T cell interactions, furthering immune system insights and reveal new therapeutic paths. - Clinical Pipeline – Therapeutics designed to treat cancers while enabling patients to continue oncology care, with opportunistic expansion into non-oncology indications leveraging ExacTcell.
- Funding and Cash Reserves – Access to line of credit and well-capitalized for current operations.
- Facilities – Drug discovery lab at CIC Philadelphia and headquarters in New Jersey. Ongoing efforts to establish internal GMP manufacturing capabilities.
"The accounting treatment of internally developed assets may not fully capture their value, but our wholly owned intellectual property, proprietary platforms, advanced AI technologies, strategic partnerships, discovery lab, and manufacturing facility in development are foundational drivers of Tevogen’s growth and long-term value creation," said Dr. Ryan Saadi, Tevogen’s Founder and CEO.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What are the main assets Tevogen Bio (TVGN) announced in August 2025?
What strategic partnerships does Tevogen Bio have for AI development?
What is Tevogen Bio's ExacTcell™ platform?
How is Tevogen Bio's financial position in 2025?
What facilities does Tevogen Bio operate in 2025?
